PRELUDE THERAPEUTICS INC Total Shareholder Rtn Amt
PRELUDE THERAPEUTICS INC (PRLD) reported Total Shareholder Rtn Amt of $67.92 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-29.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-29
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $67.92 DEF 14A · filed 2026-04-29 |
| 2024-12-31 | $29.74 DEF 14A · filed 2026-04-29 |
| 2023-12-31 | $100.00 DEF 14A · filed 2026-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |